Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE SODIUM versus PREVACID NAPRAPAC 500 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE SODIUM versus PREVACID NAPRAPAC 500 COPACKAGED.
ESOMEPRAZOLE SODIUM vs PREVACID NAPRAPAC 500 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
20-40 mg IV once daily for up to 10 days; oral: 20-40 mg once daily for 4-8 weeks for erosive esophagitis, 20 mg once daily for gastroesophageal reflux disease.
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals; clinical context: longer half-life (~2–3 hours) in slow CYP2C19 metabolizers, but acid suppression lasts longer due to irreversible binding to H+/K+-ATPase.
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Primarily hepatic metabolism (~80%) via CYP2C19 and CYP3A4; renal excretion of inactive metabolites accounts for ~80% of an oral dose, with ~20% excreted in feces via bile.
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination